Tech Tuesday – Barry Byrne
In this week’s Tech Tuesday for WCJB TV20, UF Innovate’s Loren Miranda speaks with Dr. Barry Byrne, Associate Chair of Pediatrics and Director of the UF Powell Gene Therapy Center.
Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis
Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.
24-Year-Old Researches Treatment for Her Own Crippling Disease: ‘I’m in a Race Against Time’
Shandra Trantham has Friedreich’s ataxia (FA), a rare genetic disease that is slowly robbing her of the ability to walk and talk, and can also affect her heart. FA is caused by an inability in the body to make frataxin, a protein that is necessary for normal cell function. To date, there is no cure and no approved treatments — but she’s working on one. She’s a 4th-year Ph.D. candidate in genetics and genomics at the University of Florida Powell Gene Therapy Center. Trantham works in a lab where gene therapy for FA is being fine-tuned.
Barry Byrne, MD, Ph.D.: Landscape of Awareness for Neuromuscular Disease
Barry J. Byrne, MD, Ph.D., chief medical advisor of the Muscular Dystrophy Association and associate chair of pediatrics and director at the University of Florida Powell Center for Rare Disease Research and Therapy, talked with NeurologyLive about the virtual telethon to create awareness for a number of neuromuscular diseases.
Dr. Barry Byrne Receives “See the Light” Award From the Mathew Forbes Romer Foundation
For families facing a devastating diagnosis of pediatric neurodegenerative genetic disease, Barry Byrne, M.D., Ph.D., provides a sense of hope and possibility. As director of the Powell Gene Therapy Center, the associate chair of pediatrics and the Earl and Christy Powell University Chair in Genetics at the University of Florida, Byrne has made significant contributions […]
University of Florida Received £500,000 Grant From Duchenne UK to Overcome Immunity Challenges in Gene Therapy
Duchenne UK has partnered with one of the world’s leading gene therapy teams focusing on AAV immunology. Drs. Manuela Corti and Barry Byrne at the Powell Gene Therapy Center, University of Florida, will try to temporarily modify the immune system so that anybody can be treated with gene therapy, and, if necessary, can receive repeat […]
Adapting Neurological Care Amid COVID-19
As the ongoing battle against the spread of COVID-19 continues, the medical community is learning more about the disease and at-risk populations by the day. Many symptoms and comorbidities associated with neurologic disorders place patients, especially those in the neuromuscular disease community, within those high-risk categories established by the Centers for Disease Control and Prevention […]
What Causes Duchenne Muscular Dystrophy? UF Researcher Explains
Duchenne muscular dystrophy, a genetic disease characterized by progressive muscle weakness, is present at birth in people who have the condition. In people with Duchenne, the muscles lack a protein called dystrophin, which is critical for muscle function and repair. While all people with Duchenne share a lack of or defective dystrophin, the condition can […]
Dr. Barry Byrne Featured in Denison Magazine
Barry J. Byrne, M.D., Ph.D., director of the University of Florida Powell Gene Therapy Center, a professor in Pediatrics and Molecular Genetics & Microbiology, and the associate chair in Pediatrics at the University of Florida, is studying a variety of rare diseases with specific attention to developing therapies for inherited muscle disease. His development of the Powell Gene […]